Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Apr 10
Have your own idea? Try our Stock Screener
U.S. Clinical Research and Equipment Industry Analysis
UpdatedApr 13, 2025
DataAggregated Company Financials
Companies61
- 7D1.0%
- 3M-24.6%
- 1Y-27.3%
- YTDn/a
Last week, the Clinical Research and Equipment industry hasn't moved much but Danaher is up 3.8% in that time. As for the longer term, the industry has declined 27% in the last year. Looking forward, earnings are forecast to grow by 16% annually.
Industry Valuation and Performance
Has the U.S. Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 13 Apr 2025 | US$514.0b | US$142.6b | US$10.0b | 34.6x | 51.6x | 3.6x |
| Tue, 11 Mar 2025 | US$611.4b | US$143.1b | US$9.8b | 43x | 62.7x | 4.3x |
| Thu, 06 Feb 2025 | US$673.0b | US$143.1b | US$10.4b | 39.5x | 64.7x | 4.7x |
| Sat, 04 Jan 2025 | US$651.8b | US$142.4b | US$10.2b | 43.1x | 63.9x | 4.6x |
| Mon, 02 Dec 2024 | US$672.6b | US$142.4b | US$10.2b | 44.5x | 65.7x | 4.7x |
| Wed, 30 Oct 2024 | US$677.0b | US$142.0b | US$8.3b | 36.9x | 81.9x | 4.8x |
| Fri, 27 Sep 2024 | US$727.0b | US$141.8b | US$8.5b | 38x | 85.5x | 5.1x |
| Sun, 25 Aug 2024 | US$743.2b | US$141.8b | US$8.5b | 37.4x | 87.8x | 5.2x |
| Tue, 23 Jul 2024 | US$675.6b | US$141.2b | US$12.2b | 40.7x | 55.3x | 4.8x |
| Thu, 20 Jun 2024 | US$696.9b | US$141.3b | US$12.2b | 38.6x | 57.2x | 4.9x |
| Sat, 18 May 2024 | US$742.9b | US$141.5b | US$12.5b | 38.3x | 59.4x | 5.3x |
| Mon, 15 Apr 2024 | US$711.1b | US$142.0b | US$12.8b | 42.3x | 55.6x | 5x |
| Wed, 13 Mar 2024 | US$753.3b | US$142.1b | US$12.9b | 44.6x | 58.5x | 5.3x |
| Fri, 09 Feb 2024 | US$709.3b | US$141.9b | US$12.8b | 39.1x | 55.6x | 5x |
| Sun, 07 Jan 2024 | US$684.7b | US$153.9b | US$14.2b | 36.1x | 48.3x | 4.5x |
| Tue, 05 Dec 2023 | US$651.8b | US$153.7b | US$14.0b | 35.4x | 46.5x | 4.2x |
| Thu, 02 Nov 2023 | US$572.3b | US$153.9b | US$11.1b | 29.2x | 51.3x | 3.7x |
| Sat, 30 Sep 2023 | US$670.3b | US$154.6b | US$11.2b | 33.3x | 59.8x | 4.3x |
| Mon, 28 Aug 2023 | US$712.7b | US$154.6b | US$11.2b | 32.9x | 63.6x | 4.6x |
| Wed, 26 Jul 2023 | US$744.0b | US$155.0b | US$12.1b | 29.8x | 61.3x | 4.8x |
| Fri, 23 Jun 2023 | US$691.0b | US$152.4b | US$12.5b | 29.2x | 55.3x | 4.5x |
| Sun, 21 May 2023 | US$683.1b | US$152.1b | US$12.5b | 29x | 54.8x | 4.5x |
| Tue, 18 Apr 2023 | US$742.1b | US$154.6b | US$10.8b | 30.5x | 68.7x | 4.8x |
| Thu, 16 Mar 2023 | US$701.1b | US$154.5b | US$10.9b | 30x | 64.6x | 4.5x |
| Sat, 11 Feb 2023 | US$745.6b | US$155.6b | US$8.9b | 30.6x | 84.1x | 4.8x |
| Mon, 09 Jan 2023 | US$705.6b | US$155.2b | US$8.8b | 27.6x | 80.4x | 4.5x |
| Wed, 07 Dec 2022 | US$755.0b | US$155.1b | US$8.8b | 28x | 86.1x | 4.9x |
| Fri, 04 Nov 2022 | US$699.1b | US$154.7b | US$13.0b | 26.2x | 53.8x | 4.5x |
| Sun, 02 Oct 2022 | US$700.3b | US$152.2b | US$17.3b | 23.2x | 40.5x | 4.6x |
| Tue, 30 Aug 2022 | US$773.6b | US$152.3b | US$17.3b | 29.5x | 44.7x | 5.1x |
| Thu, 28 Jul 2022 | US$797.7b | US$148.8b | US$20.2b | 32.8x | 39.5x | 5.4x |
| Sat, 25 Jun 2022 | US$724.4b | US$148.1b | US$20.1b | 30.5x | 36x | 4.9x |
| Mon, 23 May 2022 | US$736.5b | US$148.0b | US$20.0b | 31.9x | 36.7x | 5x |
| Wed, 20 Apr 2022 | US$837.9b | US$146.5b | US$25.3b | 34.5x | 33.1x | 5.7x |
Price to Earnings Ratio
33.1x
Current Industry PE
- Investors are pessimistic on the American Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 50.0x which is lower than its 3-year average PE of 60.0x.
- The 3-year average PS ratio of 4.8x is higher than the industry's current PS ratio of 3.5x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have declined 27% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does U.S. Clinical Research and Equipment compare with similar industries?
| US Market | 5.42% | |
| Healthcare | 1.93% | |
| Life Sciences | 0.99% | |
| Clinical Research and Equipment | 0.99% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| DHR Danaher | US$188.73 | 3.8% +US$5.0b | -21.3% | PE34.6x | |
| QGEN Qiagen | US$41.98 | 9.7% +US$804.0m | 1.6% | PE108.5x | |
| STVN Stevanato Group | US$21.91 | 15.2% +US$788.7m | -25.5% | PE44.8x | |
| BIO Bio-Rad Laboratories | US$245.80 | 9.0% +US$638.7m | -18.2% | PS3x | |
| RGEN Repligen | US$122.86 | 9.8% +US$613.5m | -28.4% | PS10.9x |